Cell Replacement Therapy in Parkinson’s Disease—History of Development and Prospects for Use in Clinical Practice

Standard

Cell Replacement Therapy in Parkinson’s Disease—History of Development and Prospects for Use in Clinical Practice. / Katolikova, N. V.; Malashicheva, A. B.; Gainetdinov, R. R.

In: Molecular Biology, Vol. 54, No. 6, 11.2020, p. 827-839.

Research output: Contribution to journal › Review article › peer-review

BibTeX

@article{1a6aa7e04a7e4cecb0873f2f08c0fbc1,

title = "Cell Replacement Therapy in Parkinson{\textquoteright}s Disease—History of Development and Prospects for Use in Clinical Practice",

abstract = "Parkinson's disease is a widespread neurodegenerative disease, which is characterized by the death of dopaminergic neurons in the substantia nigra of the midbrain. Clinically, the disease is manifested by tremor, bradykinesia, muscle rigidity, and other motor and non-motor symptoms that ultimately lead to disability. To date, there are only symptomatic treatment options for Parkinson's disease; therefore, the search for new approaches is one of the most important directions of therapy for this disease. In the 1970's the idea of using cell replacement therapy based on the local nature and specificity of damage to a particular type of neuron in Parkinson's disease originated. The selection of the source of cells, the method and place of introduction, indications for this operation, and peculiarities of patient management have been in development for a long time. The efficiency of cell replacement therapy has been confirmed by a number of studies on animal models. Clinical trials have already begun and several more are planned soon. This review describes the main prerequisites for the use of cell replacement therapy in Parkinson's disease, the stages of development of this method, and clinical trials that have started in the last few years.",

keywords = "cell differentiation, cell replacement therapy, embryonic stem cells, induced pluripotent stem cells, neuronal progenitors, Parkinson{\textquoteright}s disease",

author = "Katolikova, {N. V.} and Malashicheva, {A. B.} and Gainetdinov, {R. R.}",

note = "Publisher Copyright: {\textcopyright} 2020, Pleiades Publishing, Inc.",

year = "2020",

month = nov,

doi = "10.1134/S0026893320060060",

language = "English",

volume = "54",

pages = "827--839",

journal = "Molecular Biology",

issn = "0026-8933",

publisher = "Pleiades Publishing",

number = "6",

}

RIS

TY - JOUR

T1 - Cell Replacement Therapy in Parkinson’s Disease—History of Development and Prospects for Use in Clinical Practice

AU - Katolikova, N. V.

AU - Malashicheva, A. B.

AU - Gainetdinov, R. R.

PY - 2020/11

Y1 - 2020/11

N2 - Parkinson's disease is a widespread neurodegenerative disease, which is characterized by the death of dopaminergic neurons in the substantia nigra of the midbrain. Clinically, the disease is manifested by tremor, bradykinesia, muscle rigidity, and other motor and non-motor symptoms that ultimately lead to disability. To date, there are only symptomatic treatment options for Parkinson's disease; therefore, the search for new approaches is one of the most important directions of therapy for this disease. In the 1970's the idea of using cell replacement therapy based on the local nature and specificity of damage to a particular type of neuron in Parkinson's disease originated. The selection of the source of cells, the method and place of introduction, indications for this operation, and peculiarities of patient management have been in development for a long time. The efficiency of cell replacement therapy has been confirmed by a number of studies on animal models. Clinical trials have already begun and several more are planned soon. This review describes the main prerequisites for the use of cell replacement therapy in Parkinson's disease, the stages of development of this method, and clinical trials that have started in the last few years.

AB - Parkinson's disease is a widespread neurodegenerative disease, which is characterized by the death of dopaminergic neurons in the substantia nigra of the midbrain. Clinically, the disease is manifested by tremor, bradykinesia, muscle rigidity, and other motor and non-motor symptoms that ultimately lead to disability. To date, there are only symptomatic treatment options for Parkinson's disease; therefore, the search for new approaches is one of the most important directions of therapy for this disease. In the 1970's the idea of using cell replacement therapy based on the local nature and specificity of damage to a particular type of neuron in Parkinson's disease originated. The selection of the source of cells, the method and place of introduction, indications for this operation, and peculiarities of patient management have been in development for a long time. The efficiency of cell replacement therapy has been confirmed by a number of studies on animal models. Clinical trials have already begun and several more are planned soon. This review describes the main prerequisites for the use of cell replacement therapy in Parkinson's disease, the stages of development of this method, and clinical trials that have started in the last few years.

KW - cell differentiation

KW - cell replacement therapy

KW - embryonic stem cells

KW - induced pluripotent stem cells

KW - neuronal progenitors

KW - Parkinson’s disease

UR - http://www.scopus.com/inward/record.url?scp=85098704041&partnerID=8YFLogxK

U2 - 10.1134/S0026893320060060

DO - 10.1134/S0026893320060060

M3 - Review article

C2 - 33276357

AN - SCOPUS:85098704041

VL - 54

SP - 827

EP - 839

JO - Molecular Biology

JF - Molecular Biology

SN - 0026-8933

IS - 6

ER -

ID: 87888450